logo
Sign in

Chemocentryx

Biotech · Acquired

Avacopan, a CCR5 complement inhibitor small-molecule therapeutic for ANCA vasculitis

Claim this profile

Follows are private to you and power your alerts

Updated · chemocentryx.com

Sector
Biotech
Total capital
$15.6M
Federal grants
$15.5M
9 awards · 2001–2019
9.0× sector median 1 award
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$107K
1 award · Veterans Affairs
Rank in Biotech#324 of 4373
Granted patents
28
12 pending · first 2023
Rank in peer group#10 of 1449

Capital timeline

200120052009201320172021FEDERAL ↑EQUITY ↓Cumulative $15.6M$3.2M$3.2M$3.1M$500K
200120052009201320172021FEDERAL ↑EQUITY ↓Cumulative $15.6M$3.2M$3.2M

Latest events

  • Federal contractVeterans Affairs · Tavneos (avacopan) Boise Vamc$107K
  • Federal grantHealth and Human S · R01 · Phase 2 Study of Avacopan for Treatment of C3G, IND 132321, Orphan Designation 16-5590$500K
  • Federal grantHealth and Human S · R01 · Phase 2 Study of Avacopan for Treatment of C3G, IND 132321, Orphan Designation 16-5590$500K
  • Federal grantHealth and Human S · R01 · Phase 2 Studies of CCX168 for Treatment of ANCA-Vasculitis IND120784, OD14-4320$500K
  • Federal grantHealth and Human S · U19 · Chemokine Adjuvants For Biothreat Pathogen Vaccines$3.1M
  • Federal grantHealth and Human S · U19 · Chemokine Adjuvants For Biothreat Pathogen Vaccines$1.3M
  • Federal grantHealth and Human S · U19 · Chemokine Adjuvants For Biothreat Pathogen Vaccines$3.1M
Show 3 earlier federal awards
  • Federal grantHealth and Human S · U19 · Chemokine Adjuvants For Biothreat Pathogen Vaccines$3.2M
  • Federal grantHealth and Human S · U19 · Chemokine Adjuvants For Biothreat Pathogen Vaccines$3.2M
  • Federal grantHealth and Human S · Phase I · A CMV vaccine with modified immuno-modulatory properties$100K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#10 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 28 granted of 40
Show all 40 patent records

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .